Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110591 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Hongda Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shandong University of Traditional Chinese Medicine, People's Republic of China; Shandong Provincial Hospital for Skin Diseases, Shandong First Medic…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Pemphigoid, Bullous, Psoriasis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China-Yunnan Joint Fund, Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China.
Abstract (Originalsprache)
Bullous pemphigoid (BP) and psoriasis are both immune-related skin diseases. Still, the comorbidities between the two are rare, and there is no consensus on the optimal treatment strategy for BP combined with psoriasis. JAK inhibitors are emerging, molecularly targeted therapeutic agents that target the molecule of Janus kinase, a signal transducer and activator of transcription (JAK/STAT). JAK inhibitors block intracellular signaling pathways by blocking the gene transcription of key pro-inflammatory cytokines that play a central role in the pathogenesis of many inflammatory and autoimmune diseases. Tofacitinib is a first-generation JAK inhibitor. The purpose of this article is to describe the first report of the use of tofacitinib in treating BP combined with psoriasis vulgaris with significant results. According to our findings, tofacitinib may be a safe and effective treatment option for patients suffering from BP and psoriasis together. The implications of this are substantial for the guidance of treatment strategies for both comorbid conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong University of Traditional Chinese Medicine, People's Republic of China; Shandong Provincial Hospital for Skin Diseases, Shandong First Medical University, People's Republic of China; Shandong Provincial Institu…
- Shandong Provincial Hospital for Skin Diseases, Shandong First Medical University, People's Republic of China; Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, People's…
- Jinan Dermatology Prevention and Treatment Hospital, People's Republic of China.
Förderung
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China-Yunnan Joint Fund
- Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
Zitieren
APA
Li, H., Wang, H., Qiao, G., Liu, Y., Zhang, F., & Pan, F. (2023). Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110591
Vancouver
Li H, Wang H, Qiao G, Liu Y, Zhang F, Pan F. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110591
BibTeX
@article{Li2023,
author = {Li, Hongda and Wang, Honglei and Qiao, Guizhi and Liu, Yongxia and Zhang, Furen and Pan, Futang},
title = {Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110591}
}
EUVIMED